An interventional study of Swisse Nutra+ Cholesterol Balance and Placebo in Hypercholesterolemia, sponsored by Swisse Wellness Pty Ltd. Completed at 1 site in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-11.
Sponsored by Swisse Wellness Pty Ltd · Not applicable, Interventional, and Treatment
To evaluate the effects of daily consumption of 3 capsules of Swisse Nutra+ Cholesterol Balance on serum LDL-cholesterol in adults with hypercholesterolaemia compared to placebo over four months.
This is a single-centre, randomised, double-blind, placebo controlled, parallel study.
Applicants will be eligible to participate if they have hypercholesterolemia, defined by fasting LDL-cholesterol 2.5mmol/L and ≤5 mmol/L confirmed at screening visit. Participants who are otherwise healthy will be included in the study; individuals with a history of cardiovascular disease are excluded from this trial.
Following pre-screening telephone assessment, applicants will attend an in-clinic screening visit and following informed consent, their general health and eligibility for inclusion into the study will be assessed.
On Day 1 eligible participants will be randomly allocated to receive one of two study treatments (intervention or placebo). Participants will consume the assigned treatment daily for four months.
Participants will return to the clinic at months 2 and 4 for assessment of primary and secondary outcomes. Compliance, adverse events and concomitant medication use will be assessed at these visits. In addition, participants will complete an online survey at months 1 and 3 to assess protocol compliance, adverse events and use of concomitant medications. Any queries that arise from the survey will be followed up by phone call.
Dietary intakes will be assessed at the baseline and four-month visits. A final participant online survey and phone call (if needed) will be conducted one month after the 4-month visit for a final safety assessment.
1,175 studies on the registry are indexed under Hypercholesterolemia; 93 are open to participants now.
This study's enrollment of 42 is below the median of 110 across 975 interventional studies indexed under Hypercholesterolemia.
Browse Hypercholesterolemia studies →Swisse Wellness Pty Ltd is the lead sponsor of 4 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Women of (WOCBP) who:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Active treatment comprises of 3 soft gel capsules daily (with food) of Swisse Nutra+ Cholesterol Balance, a novel combination nutraceutical containing bergamot juice extract, artichoke leaf extract, hydroxytyrosol and plant sterols, totaling a daily dose of 375 mg bergamot juice extract, 150 mg artichoke leaf extract, 50 mg hydroxytyrosol and 1.8 g sunflower phytosterols. Each capsule contains 125mg of bergamot juice extract, 50mg artichoke leaf extract, 16.67mg hydroxytyrosol and 600mg plant sterols. The intervention will be administered for 4 months (112 days).
Dietary Supplement: Swisse Nutra+ Cholesterol Balance
3 soft gel capsules of matching placebo daily (total daily dose of 696 mg palm olein and 232 mg olive oil).
Dietary Supplement: Placebo
Swisse Nutra+ Cholesterol Balance is a multi-ingredient nutraceutical composition contained in a brown soft-gel capsule format. Three capsules are required per dose.Swisse Nutra+ Cholesterol Balance is a multi-ingredient formulation containing artichoke extract, bergamot juice extract, hydroxytyrosol, an antioxidant derived from olive oil and sunflower oil-derived phytosterols. All ingredients target cholesterol reduction by different and complementing mechanisms, as evidenced by human clinical trials. These ingredients have been chosen to work synergistically to alleviate hypercholesterolemia and/or dyslipidemia through multiple pathways, whereby each ingredient works via a different mechanism to lower LDL-cholesterol in the body.
Matched brown soft-gel capsule placebo containing olive oil and palm olein - no therapeutic benefit.
Change in LDL-cholesterol
Low-density lipoprotein-cholesterol (LDL-C) will be analysed using standardised methods. A Beckman AU480 clinical analyser (Beckman Coulter Inc, Brea, CA, USA) and relevant commercial enzymatic test kits will be used for analysis of serum LDL-cholesterol. Change in serum LDL-C (mmol/L) from baseline will be recorded.
Time frame: From baseline to 4 months
Serum lipid concentrations from baseline
Change in serum lipid concentrations of the following measures (total cholesterol, high-density lipoprotein-cholesterol, triglycerides, non-HDL-C, total cholesterol:HDL-cholesterol ratio, apolipoproteinA1 (apoA1), apolipoproteinB (apoB), apoB:apoA1 ratio) will be analysed. Fasting blood samples (total of \~14 ml) will be collected into vacutainers containing a clot activator for the preparation of serum. Secondary blood-based outcomes will be analysed using standardised methods. Immunoturbidimetric test kits will be used for analysis of apoA1 and apoB. Total cholesterol:HDL-cholesterol and apoB:apoA1 ratio will be calculated from the results. Non-HDL-cholesterol will be calculated as total cholesterol - HDL-cholesterol.
Time frame: From baseline to 4 months
Blood pressure changes from baseline
Resting systolic and diastolic blood pressure (mmHg) will be measured using an automated blood pressure monitor in a seated position following a 5-minute rest. The average of three measurements (separated by 2 minutes) will be recorded.
Time frame: From baseline to 4 months
Changes in HbA1c from baseline
Whole Ethylenediaminetetraacetic acid (EDTA) blood samples will be collected to analyse haemoglobin A1C (HbA1c) concentration changes during the study period. A Beckman AU480 clinical analyser (Beckman Coulter Inc, Brea, CA, USA) and relevant commercial enzymatic test kits will be used for analysis of HbA1c.
Time frame: From baseline to 4 months
Changes in plasma ox-LDL
Changes in plasma oxidised-low-density lipoprotein will be analysed by commercial ELISA kit. Vacutainers containing K2-EDTA anticoagulant will be used for the preparation of plasma. This assay will be measured on an EnVision Multilabel plate reader (Perkin Elmer, MA, USA).
Time frame: From baseline to 4 months
Changes in serum malondialdehyde
Changes in serum malondialdehyde will be analysed by commercial colorimetric assay kit. This assay will be measured on an EnVision Multilabel plate reader (Perkin Elmer, MA, USA).
Time frame: From baseline to 4 months
Changes to diet
Participant's habitual dietary intake will be assessed at Baseline and 4 month visits using the Automated Self-Administered 24-hour (ASA24-Australia) Dietary Assessment Tool, version (2016), developed and validated by the National Cancer Institute, Bethesda, MD (36). Three 24-hour recalls will be completed at each occasion. At Day 1, participants will complete the first 24-hour recall during a dietitian consultation while the subsequent 24-hour recalls will be completed by the participant at home within 7-days of Day 1 and on days as specified by the dietitian (including 2 week- and 1 weekend day). Overall, all days of the week will be covered by participants. Nutrient analysis is automated through the ASA24 program and uses the Australian Food, Supplement and Nutrient Database (AUSNUT, 2011-13).
Time frame: From baseline to 4 months
Changes in anthropometric measurements - height
Height will be measured at Screening (cm). Height will be measured using a stadiometer. Waist and hip circumference (cm) will be measured at Baseline, 2- and 4 month or Early Withdrawal visits. Waist will be measured at the top of the iliac crest with a plastic measuring tape and taken at minimal respiration for the average of three consecutive readings. Hip circumference will be measured at the largest circumference of the buttocks.
Time frame: From baseline to 4 months
Changes in anthropometric measurements - weight
Body weight (kg) will be measured at screening and Day 1 and also be collected at the 2 month, 4 month or Early Withdrawal visits. Body weight will be measured using calibrated electronic digital scales.
Time frame: Baseline to 4 months
Changes in anthropometric measurements - BMI
Body mass index (BMI) will be calculated using the formula weight (kg)/height (m)2. BMI will be assessed at screening, baseline, 2 months, and 4 months.
Time frame: Baseline to 4 months.
Changes in anthropometric measurements- WHR
Waist:hip ratio (WHR) will be calculated using the formula waist circumference (cm)/hip circumference (cm). WHR will be calculated from measurements taken at Baseline, 2 and-4 months or Early Withdrawal visits.
Time frame: Baseline to 4 months
Changes in body composition
Fat mass and fat free mass will be measured at Baseline, 2- and 4 month or Early Withdrawal visits using a multi-frequency bioelectrical impedance analysis machine with 8 tactile electrodes (InBody 770, Biospace Co. Ltd, Seoul). Measurements will be obtained after voiding. Participants will stand upright, positioning their bare feet on the footpads and their hands on the handles. A small electrical current is passed through the body, resistance is measured, and total body water and the corresponding body composition measures are calculated by the inbuilt software.
Time frame: From baseline to 4 months
Safety - Incidence of adverse events (AEs) and serious adverse events (SAEs)
All adverse events will be recorded from dosing until the end of the study (Final Safety Visit or early withdrawal). At clinic visit at month 2 and month 4 and online surveys, participants will be questioned in a non-leading manner regarding the occurrence of any adverse medical event. All AEs will be documented in the source documents and evaluated by the Medical Investigator for severity and causality to study treatment. All SAEs will be reported to the study sponsor as per standard Good Clinical Practice (GCP) requirements.
Time frame: From baseline to 4 months
Safety- Number of participants with significant changes to blood pressure over study period between groups
Vital signs will be measured by a designee while the participant is seated. Resting blood pressure (systolic/diastolic mmHG) will be measured using an automated blood pressure monitor in a seated position following a 5-minute rest. The average of three measurements (separated by 2 minutes) will be recorded.Vital signs will be performed at Screening, Baseline, 2 month and 4 month or Early Withdrawal Visit.
Time frame: Baseline to 4 months
Safety - Number of participants who fall pregnant (WOCBP only)
A urine sample will be collected at Screening, Baseline, 2 and 4 month Visit or Early Withdrawal visit in WOCBP only. Study staff will perform a dipstick urine pregnancy test and record the result in the source documents.
Time frame: Baseline to 4 months
Safety - Number of participants with significant changes to heart rate between groups
Vital signs will be measured by a designee while the participant is seated. Heart rate will be measured as beats/minute by palpating the participants' carotid and radial pulses. Vital signs will be performed at Screening, Baseline, 2 month and 4 month or Early Withdrawal Visit.
Time frame: Baseline to 4 months
Number of participants with changes to heart sounds
The Medical Investigator will perform a non-invasive physical examination of the participants' cardiovascular system by listening to heart sounds to determine whether there is a heart murmur or irregular heart beat. At Day 1 (Baseline visit) these will be reviewed to establish their baseline characteristics. A symptom directed physical exam will be conducted at 4 months or Early Withdrawal Visit.
Time frame: Baseline to 4 months
Safety - Number of participants with significant changes to respiratory rate between groups
Respiratory rate will be measured by counting the number of times the chest rises per minute while the participant is at rest. Vital signs will be performed at Screening, Baseline, 2 month and 4 month or Early Withdrawal Visit.
Time frame: Baseline to 4 months
Number of participants with changes to respiratory effort
The Medical Investigator will perform a non-invasive physical examination of the participants' lung function by observing the participants' breathing rhythm and chest movement. At Day 1 (Baseline visit) these will be reviewed to establish their baseline characteristics. A symptom directed physical exam will be conducted at 4 months or Early Withdrawal Visit.
Time frame: Baseline to 4 months
Safety - Number of participants with significant changes to core body temperature between groups
Vital signs will be measured by a designee while the participant is seated. Body temperature (°C) will be measured using a digital thermometer.
Time frame: Baseline to 4 months
Safety: Number of participants with macroscopic abnormalities of the eyes
A non-invasive physical examination will be performed by a Medical Investigator and will include an assessment of the appearance of the pupil, iris, cornea, eyelids, eyelashes, conjuctiva and periorbital are including redness, discharge, lesions, ulcers, abrasions or unusual growths. At Day 1 (Baseline visit) these will be reviewed to establish their baseline characteristics. A symptom directed physical exam will be conducted at 4 months or Early Withdrawal Visit.
Time frame: Baseline to 4 months
Safety -Number of participants with visual symptoms
Participants will be asked to self-report on any visual symptoms or changes e.g. blurriness, eye strain etc. throughout the study period. At Day 1 (Baseline visit) these will be reviewed to establish their baseline characteristics. A symptom directed physical exam will be conducted at 4 months or Early Withdrawal Visit.
Time frame: Baseline to 4 months
Safety: Number of participants with infections in the Ears, Nose, Mouth and Throat
A non-invasive physical examination will be performed by a Medical Investigator and will include * A visual assessment of the ears, nose, mouth and throat to check for signs of infection * Palpation of the cervical chain lymph nodes to check for signs of infection At Day 1 (Baseline visit) these will be reviewed to establish their baseline characteristics. A symptom directed physical exam will be conducted at 4 months or Early Withdrawal Visit.
Time frame: Baseline to 4 months
Safety: Number of participants with changes to peripheral vascular function
A non-invasive physical examination will be performed by a Medical Investigator and will include palpating the dorsal pedis pulse, posterior tibial pulse and palpation of the ankles to check for peripheral oedema. At Day 1 (Baseline visit) these will be reviewed to establish their baseline characteristics. A symptom directed physical exam will be conducted at 4 months or Early Withdrawal Visit.
Time frame: Baseline to 4 months
Safety: Number of participants with respiratory disease
The Medical Investigator will perform a non-invasive physical examination of the participants' respiratory system by listening to breath sounds to determine whether there is untreated asthma or other lung disease. At Day 1 (Baseline visit) these will be reviewed to establish their baseline characteristics. A symptom directed physical exam will be conducted at 4 months or Early Withdrawal Visit.
Time frame: Baseline to 4 months
Safety: Number of participants with changes to the gastrointestinal tract
Medical Investigator will perform a non-invasive physical exam by observing and palpating the participants' abdomen to check for surgical scars, ascites, organomegaly and abdominal discomfort. At Day 1 (Baseline visit) these will be reviewed to establish their baseline characteristics. A symptom directed physical exam will be conducted at 4 months or Early Withdrawal Visit.
Time frame: Baseline to 4 months
Safety: Changes to characteristics in physical examination - musculoskeletal
A non-invasive physical examination will be performed by a Medical Investigator and will include an assessment of joint mobility. Participants will be asked to to stand and sit back down into a chair unassisted, to reach forward and try to touch their toes, and to touch their opposite shoulder blades across their front, behind their neck and behind their back (Apley Shoulder test). At Day 1 (Baseline visit) these will be reviewed to establish their baseline characteristics. A symptom directed physical exam will be conducted at 4 months or Early Withdrawal Visit.
Time frame: Baseline to 4 months
Safety: Number of participants with changes to characteristics in skin appearance
A non-invasive physical examination will be performed by a Medical Investigator who will observe the participants' skin colour, looking for central and peripheral cyanosis, jaundice, or any skin rashes or lesions. At Day 1 (Baseline visit) these will be reviewed to establish their baseline characteristics. A symptom directed physical exam will be conducted at 4 months or Early Withdrawal Visit.
Time frame: Baseline to 4 months
Safety: Number of participants with clinically significant changes in biochemistry - AST
Fasting blood samples will be collected at Screening, Baseline, 2 Month, 4 Month and Early Withdrawal visits. Changes in Aspartate aminotransferase (AST) from baseline (U/L) will be analysed by a National Association of Testing Authorities, Australia (NATA) laboratory.
Time frame: Baseline to 4 months
Safety: Number of participants with clinically significant changes in biochemistry- ALT
Fasting blood samples will be collected at Screening, Baseline, 2 Month, 4 Month and Early Withdrawal visits. Changes in Alanine aminotransferase (ALT) from baseline (U/L) will be analysed by a National Association of Testing Authorities, Australia (NATA) laboratory.
Time frame: Baseline to 4 months
Safety: Number of participants with clinically significant changes in biochemistry - GGT
Fasting blood samples will be collected at Screening, Baseline, 2 Month, 4 Month and Early Withdrawal visits. Changes in gamma glutamyltransferase from baseline (U/L) will be analysed by a National Association of Testing Authorities, Australia (NATA) laboratory.
Time frame: Baseline to 4 months
Safety: Number of participants with clinically significant changes in biochemistry - ALP
Fasting blood samples will be collected at Screening, Baseline, 2 Month, 4 Month and Early Withdrawal visits. Changes in Alkaline phosphatase (ALP) (U/L) will be analysed by a National Association of Testing Authorities, Australia (NATA) laboratory.
Time frame: Baseline to 4 months
Safety: Number of participants with clinically significant changes in biochemistry - LD
Fasting blood samples will be collected at Screening, Baseline, 2 Month, 4 Month and Early Withdrawal visits. Changes in Lactate Dehydrogenase (U/L) will be analysed by a National Association of Testing Authorities, Australia (NATA) laboratory.
Time frame: Baseline to 4 months
Safety: Number of participants with clinically significant changes in biochemistry - creatinine
Fasting blood samples will be collected at Screening, Baseline, 2 Month, 4 Month and Early Withdrawal visits. Changes in creatinine (µmol/L) will be analysed by a National Association of Testing Authorities, Australia (NATA) laboratory.
Time frame: Baseline to 4 months
Safety: Number of participants with clinically significant changes in biochemistry - creatinine kinase
Fasting blood samples will be collected at Screening, Baseline, 2 Month, 4 Month and Early Withdrawal visits. Changes in creatinine kinase (U/L) will be analysed by a National Association of Testing Authorities, Australia (NATA) laboratory.
Time frame: Baseline to 4 months
Safety: Number of participants with clinically significant changes in biochemistry - urea nitrogen
Fasting blood samples will be collected at Screening, Baseline, 2 Month, 4 Month and Early Withdrawal visits. Changes in urea nitrogen (mmol/L) will be analysed by a National Association of Testing Authorities, Australia (NATA) laboratory.
Time frame: Baseline to 4 months
Safety: Number of participants with clinically significant changes in biochemistry - sodium
Fasting blood samples will be collected at Screening, Baseline, 2 Month, 4 Month and Early Withdrawal visits. Changes in blood sodium levels (mmol/L) will be analysed by a National Association of Testing Authorities, Australia (NATA) laboratory.
Time frame: Baseline to 4 months
Safety: Number of participants with clinically significant changes in biochemistry - potassium
Fasting blood samples will be collected at Screening, Baseline, 2 Month, 4 Month and Early Withdrawal visits. Changes in blood potassium levels (mmol/L) will be analysed by a National Association of Testing Authorities, Australia (NATA) laboratory.
Time frame: Baseline to 4 months
Safety: Number of participants with clinically significant changes in biochemistry - chloride
Fasting blood samples will be collected at Screening, Baseline, 2 Month, 4 Month and Early Withdrawal visits. Changes in blood chloride levels (mmol/L) will be analysed by a National Association of Testing Authorities, Australia (NATA) laboratory.
Time frame: Baseline to 4 months
Safety: Number of participants with clinically significant changes in biochemistry - bicarbonate
Fasting blood samples will be collected at Screening, Baseline, 2 Month, 4 Month and Early Withdrawal visits. Changes in blood bicarbonate levels (mmol/L) will be analysed by a National Association of Testing Authorities, Australia (NATA) laboratory.
Time frame: Baseline to 4 months
Safety: Number of participants with clinically significant changes in biochemistry - urea
Fasting blood samples will be collected at Screening, Baseline, 2 Month, 4 Month and Early Withdrawal visits. Changes in blood urea levels (mmol/L) will be analysed by a National Association of Testing Authorities, Australia (NATA) laboratory.
Time frame: Baseline to 4 months
Safety: Number of participants with clinically significant changes in biochemistry - calcium
Fasting blood samples will be collected at Screening, Baseline, 2 Month, 4 Month and Early Withdrawal visits. Changes in calcium levels (mmol/L) will be analysed by a National Association of Testing Authorities, Australia (NATA) laboratory.
Time frame: Baseline to 4 months
Safety: Number of participants with clinically significant changes in biochemistry - CRP
Fasting blood samples will be collected at Screening, Baseline, 2 Month, 4 Month and Early Withdrawal visits. Changes in C-reactive protein levels (CRP) measured as mg/L will be analysed by a National Association of Testing Authorities, Australia (NATA) laboratory.
Time frame: Baseline to 4 months
Safety: Number of participants with clinically significant changes in biochemistry - uric acid
Fasting blood samples will be collected at Screening, Baseline, 2 Month, 4 Month and Early Withdrawal visits. Changes in uric acid measured as mol/mol will be analysed by a National Association of Testing Authorities, Australia (NATA) laboratory.
Time frame: Baseline to 4 months
Safety: Number of participants with clinically significant changes in biochemistry - phosphate
Fasting blood samples will be collected at Screening, Baseline, 2 Month, 4 Month and Early Withdrawal visits. Changes in phosphate (mmol/L) will be analysed by a National Association of Testing Authorities, Australia (NATA) laboratory.
Time frame: Baseline to 4 months
Safety: Number of participants with clinically significant changes in biochemistry - albumin
Fasting blood samples will be collected at Screening, Baseline, 2 Month, 4 Month and Early Withdrawal visits. Changes in albumin (g/L) will be analysed by a National Association of Testing Authorities, Australia (NATA) laboratory.
Time frame: Baseline to 4 months
Safety: Number of participants with clinically significant changes in biochemistry - globulins
Fasting blood samples will be collected at Screening, Baseline, 2 Month, 4 Month and Early Withdrawal visits. Changes in globulins (g/L) will be analysed by a National Association of Testing Authorities, Australia (NATA) laboratory.
Time frame: Baseline to 4 months
Safety: Number of participants with clinically significant changes in biochemistry - protein
Fasting blood samples will be collected at Screening, Baseline, 2 Month, 4 Month and Early Withdrawal visits. Changes in protein (g/L) will be analysed by a National Association of Testing Authorities, Australia (NATA) laboratory.
Time frame: Baseline to 4 months
Safety: Number of participants with clinically significant changes in biochemistry - total bilirubin
Fasting blood samples will be collected at Screening, Baseline, 2 Month, 4 Month and Early Withdrawal visits. Changes in total bilirubin (umol/L) will be analysed by a National Association of Testing Authorities, Australia (NATA) laboratory.
Time frame: Baseline to 4 months
Safety: Number of participants with clinically significant changes in biochemistry - glucose
Fasting blood samples will be collected at Screening, Baseline, 2 Month, 4 Month and Early Withdrawal visits. Changes in fasting glucose (mmol/L) will be analysed by a National Association of Testing Authorities, Australia (NATA) laboratory.
Time frame: Baseline to 4 months
Safety: Number of participants with clinically significant changes in haematology - RDW
Fasting blood samples will be collected at Screening, Baseline, 2 Month, 4 Month and Early Withdrawal visits. Changes in red cell distribution (RDW) will be analysed by a National Association of Testing Authorities, Australia (NATA) laboratory.
Time frame: Baseline to 4 months
Safety: Number of participants with clinically significant changes in haematology - haemoglobin
Fasting blood samples will be collected at Screening, Baseline, 2 Month, 4 Month and Early Withdrawal visits. Changes in haemoglobin (g/L) will be analysed by a National Association of Testing Authorities, Australia (NATA) laboratory.
Time frame: Baseline to 4 months
Safety: Number of participants with clinically significant changes in haematology - RBC
Fasting blood samples will be collected at Screening, Baseline, 2 Month, 4 Month and Early Withdrawal visits. Changes in red blood cell count (RBC) will be analysed by a National Association of Testing Authorities, Australia (NATA) laboratory.
Time frame: Baseline to 4 months
Safety: Number of participants with clinically significant changes in haematology - PCV
Fasting blood samples will be collected at Screening, Baseline, 2 Month, 4 Month and Early Withdrawal visits. Changes in packed cell volume (PCV) will be analysed by a National Association of Testing Authorities, Australia (NATA) laboratory.
Time frame: Baseline to 4 months
Safety: Number of participants with clinically significant changes in haematology - MCV
Fasting blood samples will be collected at Screening, Baseline, 2 Month, 4 Month and Early Withdrawal visits. Changes in mean cell volume (MCV) will be analysed by a National Association of Testing Authorities, Australia (NATA) laboratory.
Time frame: Baseline to 4 months
Safety: Number of participants with clinically significant changes in haematology - MCHC
Fasting blood samples will be collected at Screening, Baseline, 2 Month, 4 Month and Early Withdrawal visits. Changes in mean cell hemoglobin concentrations (MCHC) measured as g/L will be analysed by a National Association of Testing Authorities, Australia (NATA) laboratory.
Time frame: Baseline to 4 months
Safety: Number of participants with clinically significant changes in haematology - platelets
Fasting blood samples will be collected at Screening, Baseline, 2 Month, 4 Month and Early Withdrawal visits. Changes in the number of platelets will be analysed by a National Association of Testing Authorities, Australia (NATA) laboratory.
Time frame: Baseline to 4 months
Safety: Number of participants with clinically significant changes in haematology - white cell count (WCC)
Fasting blood samples will be collected at Screening, Baseline, 2 Month, 4 Month and Early Withdrawal visits. Changes in the number of white cells will be analysed by a National Association of Testing Authorities, Australia (NATA) laboratory.
Time frame: Baseline to 4 months
Safety: Number of participants with clinically significant changes in haematology - neutrophils
Fasting blood samples will be collected at Screening, Baseline, 2 Month, 4 Month and Early Withdrawal visits. A white cell count differential test will be conducted. Changes in the number of neutrophils will be analysed by a National Association of Testing Authorities, Australia (NATA) laboratory.
Time frame: Baseline to 4 months
Safety: Number of participants with clinically significant changes in haematology - lymphocytes
Fasting blood samples will be collected at Screening, Baseline, 2 Month, 4 Month and Early Withdrawal visits. A white cell count differential test will be conducted. Changes in the number of lymphocytes will be analysed by a National Association of Testing Authorities, Australia (NATA) laboratory.
Time frame: Baseline to 4 months
Safety: Number of participants with clinically significant changes in haematology - monocytes
Fasting blood samples will be collected at Screening, Baseline, 2 Month, 4 Month and Early Withdrawal visits. A white cell count differential test will be conducted. Changes in the number of monocytes will be analysed by a National Association of Testing Authorities, Australia (NATA) laboratory.
Time frame: Baseline to 4 months
Safety: Number of participants with clinically significant changes in haematology - eosinophils
Fasting blood samples will be collected at Screening, Baseline, 2 Month, 4 Month and Early Withdrawal visits. A white cell count differential test will be conducted. Changes in the number of eosinophils will be analysed by a National Association of Testing Authorities, Australia (NATA) laboratory.
Time frame: Baseline to 4 months
Safety: Number of participants with clinically significant changes in haematology - basophils
Fasting blood samples will be collected at Screening, Baseline, 2 Month, 4 Month and Early Withdrawal visits. A white cell count differential test will be conducted. Changes in the number of basophils will be analysed by a National Association of Testing Authorities, Australia (NATA) laboratory.
Time frame: Baseline to 4 months
Plan to share: No
No publications or documents are linked to this record.
Ran from Apr 2021 to primary completion in Oct 2021, 5 months.
Of 151 interventional studies with no phase under Hypercholesterolemia, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 35. This study's 5 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Swisse Wellness Pty Ltd